While this happened, Exane BNP Paribas initiated its Astrazeneca plc ADR [AZN] rating to an Outperform in a research note published on April 15, 2025; the price target was $75. A number of analysts have revised their coverage, including UBS’s analysts, who increased its forecast for the stock in mid February from “a Neutral” to “a Buy”. Morgan Stanley began covering AZN with “an Overweight” recommendation on February 12, 2025. UBS revised its rating on November 20, 2024. It rated AZN as “a Neutral” which previously was an “a Sell”.
Price Performance Review of AZN
On Friday, Astrazeneca plc ADR [NASDAQ:AZN] saw its stock jump 0.40% to $67.57. Over the last five days, the stock has lost -6.72%. Astrazeneca plc ADR shares have risen nearly 3.13% since the year began. Nevertheless, the stocks have fallen -11.46% over the past one year. While a 52-week high of $87.68 was reached on 03/05/25, a 52-week low of $61.24 was recorded on 04/09/25. SMA at 50 days reached $71.94, while 200 days put it at $73.34.
Levels Of Support And Resistance For AZN Stock
The 24-hour chart illustrates a support level at 67.18, which if violated will result in even more drops to 66.80. On the upside, there is a resistance level at 68.29. A further resistance level may holdings at 69.02. The Relative Strength Index (RSI) on the 14-day chart is 41.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.63, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.97%. Stochastics %K at 26.91% indicates the stock is a holding.
